Annovis Bio Files Provisional Patent For New Manufacturing Process Of Crystalline Form Of Buntanetap), Which Has Demonstrated Exceptional Stability And Efficacy
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio has filed a provisional patent for a new manufacturing process of a crystalline form of buntanetap, which has shown exceptional stability and efficacy. The process offers significant benefits, including excellent yields and a purer product. The CMC protocol has been submitted to the FDA for discussion in July.
June 27, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Annovis Bio has filed a provisional patent for a new manufacturing process of a crystalline form of buntanetap, which has demonstrated exceptional stability and efficacy. The process offers significant benefits, including excellent yields and a purer product. The CMC protocol has been submitted to the FDA for discussion in July.
The filing of a provisional patent for a new manufacturing process that improves the stability and efficacy of buntanetap is a positive development for Annovis Bio. The submission of the CMC protocol to the FDA and the upcoming discussion in July indicate progress towards regulatory approval, which could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100